Composition and method for generating immunity to
View Patent ↗Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi , including administering to the subject an effective amount of the immunogenic composition
1. An immunogenic composition, comprising
a peptide, wherein consecutive amino acids of the peptide comprise consecutive amino acids of SEQ ID NO:1 and the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-193 of SEQ ID NO:1, 187-194 of SEQ ID NO:1, 188-195 of SEQ ID NO:1, 189-196 of SEQ ID NO:1, and any combination of two or more of the foregoing, and
one or more adjuvants.
2. The immunogenic composition of claim 1 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-218 of SEQ ID NO:1, 187-218 of SEQ ID NO:1, 188-218 of SEQ ID NO:1, 189-218 of SEQ ID NO:1, and any combination of two or more of the foregoing.
3. The immunogenic composition of claim 1 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 1-193 of SEQ ID NO:1, 1-194 of SEQ ID NO:1, 1-195 of SEQ ID NO:1, 1-196 of SEQ ID NO:1, and any combination of two or more of the foregoing.
4. The immunogenic composition of claim 1 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-222 of SEQ ID NO:1, 187-222 of SEQ ID NO:1, 188-222 of SEQ ID NO:1, 189-222 of SEQ ID NO:1, and any combination of two or more of the foregoing.
5. The immunogenic composition of claim 1 , wherein the peptide comprises amino acids 1-218 of SEQ ID NO:1.
6. The immunogenic composition of claim 1 , wherein the peptide comprises SEQ ID NO:1.
7. The immunogenic composition of claim 1 , wherein the peptide is covalently linked to an amino acid sequence comprising SEQ ID NO:2.
8. The immunogenic composition of claim 7 , wherein a C-terminal amino acid of the peptide is covalently linked to an amino acid sequence comprising SEQ ID NO:2.
9. The immunogenic composition of claim 4 , further comprising a covalent cross-link between the peptide and an amino acid sequence comprising SEQ ID NO:2, wherein the cross-link comprises a thioether bond to the amino acid of the peptide corresponding to amino acid 222 of SEQ ID NO:1 and an amine linkage to a lysine amino acid of SEQ ID NO:2.
10. The immunogenic composition of claim 1 , wherein at least one of the one or more adjuvants comprises aluminum salt, AS04, AS03, monophosphoryl lipid A, poly(I:C), a CpG DNA adjuvant, MF59, an emulsion adjuvant comprising squalene and water, a combination adjuvant comprising block copolymer CRL-8300, squalene, and a sorbitan monooleateor, N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium salt (DOTAP), 3 β-[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-chol liposome), or SEQ ID NO:2.
11. A method of vaccinating a subject against Borrelia burgdorferi , comprising
administering to the subject an effective amount of an immunogenic composition comprising a peptide and one or more adjuvants,
wherein consecutive amino acids of the peptide comprise consecutive amino acids of SEQ ID NO:1 and the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-193 of SEQ ID NO:1, 187-194 of SEQ ID NO:1, 188-195 of SEQ ID NO:1, 189-196 of SEQ ID NO:1, and any combination of two or more of the foregoing.
12. The method of claim 11 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-218 of SEQ ID NO:1, 187-218 of SEQ ID NO:1, 188-218 of SEQ ID NO:1, 189-218 of SEQ ID NO:1, and any combination of two or more of the foregoing.
13. The method of claim 11 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 1-193 of SEQ ID NO:1, 1-194 of SEQ ID NO:1, 1-195 of SEQ ID NO:1, 1-196 of SEQ ID NO:1, and any combination of two or more of the foregoing.
14. The method of claim 11 , wherein the consecutive amino acids of SEQ ID NO:1 are selected from the group consisting of amino acids 186-222 of SEQ ID NO:1, 187-222 of SEQ ID NO:1, 188-222 of SEQ ID NO:1, 189-222 of SEQ ID NO:1, and any combination of two or more of the foregoing.
15. The method of claim 11 , wherein the peptide comprises amino acids 1-218 of SEQ ID NO:1.
16. The method of claim 11 , wherein the peptide comprises SEQ ID NO:1.
17. The method of claim 11 , wherein the peptide is covalently linked to an amino acid sequence comprising SEQ ID NO:2.
18. The method of claim 14 , wherein a C-terminal amino acid of the peptide is covalently linked to an amino acid sequence comprising SEQ ID NO:2.
19. The method of claim 14 , wherein the immunogenic composition further comprises a covalent cross-link between the peptide and an amino acid sequence comprising SEQ ID NO:2, wherein the cross-link comprises a thioether bond to the amino acid of the peptide corresponding to amino acid 222 of SEQ ID NO:1 and an amine linkage to a lysine amino acid of SEQ ID NO:2.
20. The method of claim 11 , wherein at least one of the one or more adjuvants comprises aluminum salt, AS04, AS03, monophosphoryl lipid A, poly(I:C), a CpG DNA adjuvant, MF59, an emulsion adjuvant comprising squalene and water, a combination adjuvant comprising block copolymer CRL-8300, squalene, and a sorbitan monooleateor, N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium salt (DOTAP), 3 β-[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-chol liposome), or SEQ ID NO:2.